bioRxiv Science⌕ Search

Biology subjects

Sankar, M.

Publications and source records attributed to Sankar, M..

2 recordsLinked to original sources

A Functional Analysis of a Resorbable Citrate-based Composite Tendon Anchor

Orthopaedic fixation seeks solutions to the challenges of non-union, reconstructive surgery, and soft tissue injuries by providing stability and tissue alignment during the healing process. Risks associated with fixation devices such as peri-implant resorption, implant loosening and sub-optimal device resorption remain a significant challenge in the development of transient fixation devices. Osteomimetic biomaterials, and in particular, bio-resorbable polymer composites designed to match the mineral phase content of native bone have been shown to exhibit osteoinductive and osteoconductive properties in vivo and have been used in bone fixation for the past 2 decades. However, the specific signalling pathways driving the osteogenic response to these biomaterials remain largely unknown. In this study a resorbable, bioactive, and mechanically robust citrate-based composite, formulated from poly(octamethylene citrate) (POC) and hydroxyapatite (HA) (POC-HA) was investigated as a potential orthopedic biomaterial. In vitro analysis with human Mesenchymal Stem Cells (hMSCs) indicated that POC-HA composite materials supported cell adhesion, growth, and proliferation and increased calcium deposition, alkaline phosphatase production, the expression of osteogenic specific genes and activation of canonical pathways leading to osteoinduction and osteoconduction. Further in vivo evaluation of a POC-HA tendon fixation device in a sheep metaphyseal model indicated the regenerative and remodelling potential of this citrate-based composite material in orthopedic applications.

bioengineering↗

BMPR2 inhibits activin- and BMP-signaling via wild type ALK2

Activin A is a member of the TGF-{beta} superfamily and activates the transcription factors SMAD2/3 through the ALK4 type 1 receptor. Activin A has also been shown to activate SMAD1/5/8 through mutated variants of the type 1 receptor ALK2. Interestingly, we here show that both activin A and activin B could activate SMAD1/5/8 through endogenous wild type ALK2 in multiple myeloma cells. Knockdown of the type 2 receptor BMPR2 strongly potentiated activin A- and activin B-induced SMAD1/5/8 activation and subsequent cell death. Furthermore, activity of BMP6, BMP7 or BMP9, which also signal via ALK2, was potentiated by BMPR2 knockdown. Similar results were seen in HepG2 liver carcinoma cells. We propose that BMPR2 inhibited ALK2-mediated signaling by preventing ALK2 from oligomerizing with the type 2 receptors ACVR2A and ACVR2B, necessary for ALK2 activation by activins and several BMPs in these cells. In conclusion, BMPR2 could be explored as a possible target for therapy in patients with multiple myeloma.\n\nSummary StatementThe activation of SMAD1/5/8 via endogenous wild type ALK2 by activin A, activin B, and certain BMPs was enhanced when BMPR2 levels were knocked down.

cell biology↗